Tandem Diabetes Care Inc
NASDAQ:TNDM

Watchlist Manager
Tandem Diabetes Care Inc Logo
Tandem Diabetes Care Inc
NASDAQ:TNDM
Watchlist
Price: 30.81 USD 0.23% Market Closed
Market Cap: 2B USD
Have any thoughts about
Tandem Diabetes Care Inc?
Write Note

Tandem Diabetes Care Inc
Stock-Based Compensation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Tandem Diabetes Care Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Tandem Diabetes Care Inc
NASDAQ:TNDM
Stock-Based Compensation
$96m
CAGR 3-Years
19%
CAGR 5-Years
14%
CAGR 10-Years
21%
Becton Dickinson and Co
NYSE:BDX
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Stryker Corp
NYSE:SYK
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbott Laboratories
NYSE:ABT
Stock-Based Compensation
$676m
CAGR 3-Years
2%
CAGR 5-Years
6%
CAGR 10-Years
11%
Intuitive Surgical Inc
NASDAQ:ISRG
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Tandem Diabetes Care Inc
Glance View

Market Cap
2B USD
Industry
Health Care

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. The company is headquartered in San Diego, California and currently employs 2,000 full-time employees. The company went IPO on 2013-11-13. The firm is focused on the design, development, and commercialization of technology solutions for people living with diabetes. The firm's manufacturing, sales, and support activities principally focus on its flagship pump platform, the t:slim X2, and its complementary product offerings. Its t:slim X2 is based on Company's technology platform and is the smallest durable insulin pump available in the United States. The firm has commercially offered two different automated insulin dosing (AID) algorithms on t:slim X2, including Control-IQ technology, which is an advanced hybrid-closed loop feature, designed to help increase a user's time in their targeted glycemic range, and Food and Drug Administration (FDA) to deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar based on continuous glucose monitoring (CGM) readings.

TNDM Intrinsic Value
45.81 USD
Undervaluation 33%
Intrinsic Value
Price

See Also

What is Tandem Diabetes Care Inc's Stock-Based Compensation?
Stock-Based Compensation
96m USD

Based on the financial report for Sep 30, 2024, Tandem Diabetes Care Inc's Stock-Based Compensation amounts to 96m USD.

What is Tandem Diabetes Care Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
21%

Over the last year, the Stock-Based Compensation growth was 7%. The average annual Stock-Based Compensation growth rates for Tandem Diabetes Care Inc have been 19% over the past three years , 14% over the past five years , and 21% over the past ten years .

Back to Top